Skip to main content

Covid-19: UAE officially registers Chinese-produced vaccine for use

Health ministry cites trials showing vaccine as 86 percent effective
Chinese pharmaceutical company Sinopharm's vaccine has been undergoing third-phase trials in the Emirates since July (AFP)

The UAE has officially approved a Chinese-produced vaccine for Covid-19, citing third-phase trial analysis saying it was 86 percent effective.

The country's health ministry on Wednesday announced the "official registration" of the vaccine produced by Chinese drug giant Sinopharm, state news agency WAM said, without elaborating on how it would be used.

The vaccine has been undergoing third-phase trials in the Emirates since July, and it was approved for emergency use for healthcare workers in September.

"The announcement is a significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine," WAM said.

Israel returns non-Israelis on flight from South Korea amid coronavirus fears
Read More »

UAE health officials have reviewed Sinopharm's interim analysis of the third-phase trials which shows it is 86 percent effective against coronavirus, the report said.

"The analysis also shows the vaccine to have a 99 percent seroconversion rate of neutralising antibodies and 100 percent effectiveness in preventing moderate and severe cases of the disease.

"Furthermore, the analysis shows no serious safety concerns."

China has four vaccine products in the final stages of development, three of which - including Sinopharm - use an inactivated form of the novel coronavirus to boost immunity.

This means they only need to be refrigerated and can be easily distributed, compared to jabs developed by rivals Pfizer and BioNTech or Moderna, which have reported efficacy of 95 percent and 94 percent respectively, but which need to be transported at minus 70 degrees Celsius and minus 20 degrees Celsius. 

No data released

However, Chinese drugmakers have not released any data on their vaccines' safety or efficacy.

Chinese vaccine makers also have chequered reputations, after major scandals at home involving expired or poor-quality products. While the Chinese government's domestic handling of the virus has won support within the country, overseas buyers are cautious.

Chinese vaccine frontrunners Sinovac and Sinopharm have pre-orders for around 500m doses in total by mid-November, according to data from London science information consultancy Airfinity, mostly from countries that have participated in trials.

Two vaccines have undergone third-phase trials in the UAE: the Sinopharm project and Russia's Sputnik V, named after the Soviet-era satellite.

Dubai ruler Sheikh Mohammed bin Rashid Al-Maktoum said in November that he had received an experimental coronavirus vaccine, joining other top UAE officials to take part in the trials.

Middle East Eye delivers independent and unrivalled coverage and analysis of the Middle East, North Africa and beyond. To learn more about republishing this content and the associated fees, please fill out this form. More about MEE can be found here.